Some stomach tumors are difficult for immune treatments to see. This study found that quieting one gene can make tumor cells sound an internal alarm, drawing stronger immune attacks and helping treatment work better. Cancer immunotherapy is limited when the tumor’s surroundings suppress immune activity.

The study found that a signal made inside tumor cells plays a central role in regulating those surroundings. The key switch is KDM3A. When it is overactive, it suppresses that internal immune signal; when KDM3A is blocked, hidden viral-like sequences become active and promote the signal instead.

That change strengthens immune cells that attack tumors, reduces immune cells that restrain attacks, and, together with anti-PD1 treatment, inhibits tumor growth. The analysis pointed to KDM3A as an important regulator of the immune signal made inside tumor cells, and as a possible target for changing the tumor’s surroundings.

So the central question became simple: could reducing KDM3A change the tumor cell’s own immune signal, which KDM3A was hypothesized to regulate? To test that idea, KDM3A was removed from both mouse and human stomach tumor cells.

Removing it, or blocking it with a chemical, increased genes switched on by immune signals. Removing KDM3A also increased release of the immune signal itself, while key proteins that pass this message through the cell became more active.

In other words, the change was not limited to one genetic readout: the whole internal immune response became stronger after KDM3A was blocked. The team tested whether the heightened interferon response relied on endogenous retroviruses, while comparing double-stranded RNA and DNA sensing pathways.

The resulting alarm travels through a messenger pathway called MAVS, which carries the warning from these double-stranded genetic fragments into the cell’s immune response. In sgKDM3A-treated human AGS cells, reducing MAVS significantly decreased immune-stimulated gene expression and phosphorylation of the key response protein IRF3.

When KDM3A is blocked, normally silent viral-like genetic material becomes more active, producing more double-stranded RNA inside the cells. That RNA switches on the MAVS–interferon alarm system, linking the treatment directly to the cells’ antiviral response.

The immune consequences appeared inside tumors. Tumors made from cells lacking KDM3A contained more immune cells capable of attacking, and fewer regulatory immune cells that hold attacks back. The findings also linked KDM3A with weaker internal immune signaling and poorer response to immunotherapy in people with gastric cancer.

The strongest test combined KDM3A removal with anti-PD1 treatment in mice. Tumor growth was significantly suppressed compared with the control group or either treatment alone. In C57BL/6 mice bearing MC38 tumors, combining KDM3A ablation with anti-PD-one significantly suppressed tumor growth compared with controls or either treatment alone.

The study notes that knocking down or knocking out a group of ERVs is technically challenging, and that specific KDM3A inhibitors are currently lacking. However, restoring KDM3A reversed the increases in the chemical mark, the viral-like sequences, and the immune-response activity, supporting the proposed chain of events.

For patients, the practical promise is not an available KDM3A treatment at present, because specific KDM3A inhibitors are currently lacking. The study instead points toward the future development of more specialized KDM3A inhibitors as a possible therapeutic direction for cancer treatment.

The central finding is that blocking KDM3A can awaken hidden viral-like signals inside tumor cells, strengthen immune activity, and improve anti-PD1 treatment in mice. That points toward a possible way to make resistant gastric tumors more treatable.